Skip to main content
. Author manuscript; available in PMC: 2019 Oct 1.
Published in final edited form as: Hepatology. 2018 May 21;68(4):1574–1588. doi: 10.1002/hep.29857

Fig. 5.

Fig. 5

FEX increases GLP-1 secretion and improves insulin sensitivity in db/db mice. db/db mice (n=6 in each group) were treated by oral gavage with FEX (30 mg/Kg) + sitagliptin (3 mg/Kg) or vehicle (0.2% DMSO) + sitagliptin (3 mg/Kg) for 9 days. (A) Effect of FEX treatment on fat mass and lean mass in db/db mice. (B) Effect of FEX treatment on serum lipid profiles in db/db mice. (C) GLP-1 secretion assay of FEX in db/db mice. (D) Oral glucose tolerance assay of effect of FEX in db/db mice. (E) Insulin tolerance test of effect of FEX in db/db mice. (F) Effect of FEX on phosphorylation of liver AKT473 and ACC-1 in db/db mice. Each lane represents one mouse (n=3 per group). An “*” indicates statistically significant difference between treated vs. vehicle control (p ≤ 0.05), determined by Student’s t-test.